Synaptogenix 2021 Investor Presentation

Synaptogenix is developing restorative therapeutics for neurodegenerative diseases and developmental disorders, focusing on Bryostatin-1 for Alzheimer's and cognitive diseases. The company has completed two Phase II pilot studies demonstrating clinically meaningful restoration of cognitive function and regeneration of cerebral connections, with partnerships including the National Cancer Institute and National Institute of Aging.